This project was supported by the National Natural Science Foundation of China, Shanghai Commission of Science & Technology, Ministry of Science and Technology of China (973 & 863 Program Projects), National Key projects for New Drug Development and Manufacture, Shanghai Pudong Commis- sion of Science & Technology and Shanghai Leading Academic Discipline Project (B905). Special thanks to the study subjects and referring physicians for their participation in this study.
Aim: To evaluate the pharmacokinetics (PK), pharmacodynamics (PD) and primary tolerability of an anti-CD11a monoclonal antibody (CMABO01) in Chinese healthy volunteers and psoriatic patients. Methods: Two open...